European Partnership for Personalised Medicine (EP PerMed)

Czech version

Authors: Judita Kinkorová
Authors‘ workplace: Biobanka LF UK a FN Plzeň ; Oddělení imunochemické diagnostiky FN Plzeň
Published in: Čas. Lék. čes. 2026; 165: 69-73
Category: Review Article

Overview

Personalised medicine represents a key direction of modern healthcare, enabling the adaptation of prevention, diagnosis and treatment based on individual patient characteristics. The European Partnership for Personalised Medicine (EP PerMed) was established as a strategic European Union initiative to coordinate research, innovation and implementation of personalised medicine across Member States.

This article provides a comprehensive overview of the origin, objectives, programmes and major challenges of EP PerMed, with a particular focus on its relevance for clinicians and researchers and on the participation of the Czech Republic. Special attention is dedicated to the role of the Czech Health Research Council (AZV ČR) as a key national coordinating and funding body facilitating the involvement of Czech teams in EP PerMed joint transnational calls. The article discusses benefits and future perspectives of personalised medicine in both the European and Czech contexts.

Keywords:

personalised medicine – EP PerMed – European partnerships – health research – AZV ČR – clinical research

Sources

The Strategic Research and Innovation Agenda (SRIA) for Personalised Medicine (PM). ICPerMed, 2023. Dostupné na: www.icpermed.eu/wp-content/uploads/EPPerMed-SRIA.pdf
Personalised medicine –⁠ Health research and innovation. European Commission, Directorate‑General for Research and Innovation, 2020. Dostupné na: https://research‑and‑innovation.ec.europa.eu/research‑area/health/personalised‑medicine
Collaboration and Networking. European Partnership for Personalised Medicine (EP PerMed), 2023. Dostupné na: www.eppermed.eu/get-involved/collaboration-and-networking
European Partnership for Personalised Medicine (EP PerMed) (Project ID 101137129). European Commission, Community Research and Development Information Service (CORDIS), 2023. Dostupné na: https://cordis.europa.eu/project/id/101137129
Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases (CARMEN2026). EP PerMed Joint Transnational Call (JTC), 2026. Dostupné na: www.eppermed.eu/funding-projects/calls/jtc2026
Council conclusions on personalised medicine for patients. Council of the European Union, 2015. Dostupné na: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52015XG1217(01)
Action Plan. Actionable Research and Support Activities. ICPerMed, 2016. Dostupné na: www.icpermed.eu/wp-content/uploads/ICPerMed_Actionplan_2017_web.pdf
European Partnerships in Horizon Europe. European Commission, 2026. Dostupné na: https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe/european-partnerships-horizon-europe_en
Jørgensen JT. Twenty years with personalized medicine: past, present, and future of individualized pharmacotherapy. Oncologist 2019; 24 (7): e432–e440.
Personalised medicine. European Commision, Public Health, 2026. Dostupné na: https://health.ec.europa.eu/medicinal-products/product-types/personalised-medicine_en
Di Sanzo M, Cipolloni L, Borro M, et al. Clinical applications of personalized medicine: a new paradigm and challenge. Curr Pharm Biotechnol 2017; 18 (3): 194–203.
Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril 2018; 109 (6): 952–963.
Personalized Medicine 2020 and beyond –⁠ Preparing Europe for leading the global way (PerMed). European Commission, Community Research and Development Information Service (CORDIS), 2016. Dostupné na: https://cordis.europa.eu/project/id/602139/reporting
Norris RP, Dew R, Sharp L et al. Are there socio‑economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta‑analysis. BMC Medicine 2020; 18 : 282.
1^stEP PerMed Round Table. De-risking Innovation in Personalised Medicine. ICPerMed, 2024. Dostupné na: www.icpermed.eu/wp-content/uploads/ICPerMed_WorkshopReport_Madrid_2019.pdf
Workshop Report. Second ICPerMed Workshop ICPerMed, 2019. Dostupné na: www.icpermed.eu/wp-content/uploads/ICPerMed_WorkshopReport_Madrid_2019.pdf
A European standardization framework for data integration and data-driven in silico models for personalized medicine. Project H2020: EU-STANDS4PM. European Commission, Community Research and Development Information Service (CORDIS), 2018. Dostupné na: https://cordis.europa.eu/project/id/825843/results
Program na podporu zdravotnického aplikovaného výzkumu na léta 2024–2030. Podprogram 3: Evropská partnerství v oblasti zdraví. AZV ČR, 2024. Dostupné na: https://mzd.gov.cz/wp-content/uploads/2025/05/Program-na-podporu-zdravotnickeho-aplikovaneho-vyzkumu-na-leta-2024-2030-.pdf
Stefanicka‑Wojtas D. Kurpas D. Personalised medicine –⁠ Implementation to the healthcare system in Europe (focus group discussions). J Pers Med 2023; 13 : 380.
Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases (CARMEN2026). Guidelines for Applicants. EP PerMed Joint Transnational Call (JTC), 2026. Dostupné na: www.eppermed.eu/wp-content/uploads/EPPerMed_JTC2026_CARMEN2026_GuidelinesApplicants.pdf
Vogenberg FR, Barash CI, Pursel M. Personalized medicine part 2: ethical, legal, and regulatory issues. P&T 2010; 35 : 624–642.
Test and Demonstration of Multimodal Data Approaches for Personalised Medicine (“MultiPMData2026”) Research, Innovation and Technology Call. EP PerMed, 2026. Dostupné na: www.eppermed.eu/wp-content/uploads/EPPerMed_JTC2026_CARMEN2026_GuidelinesApplicants.pdf
Evidence Framework for the Monitoring and Evaluation of Horizon Europe (SWD(2023)132 final). European Commission, Directorate‑General for Research and Innovation, 2023. Dostupné na: https://research-and-innovation.ec.europa.eu/system/files/2023-05/swd-2023-132-monitoring-evaluation-he.pdf
Mohr AE, Ortega‑Santos CP, Whisner C M et al. Navigating challenges and opportunities in multi‑omics integration for personalized healthcare. Biomedicines 2024; 12 : 1496.
Alum EU, Ugwu OPC. Artificial intelligence in personalized medicine: transforming diagnosis and treatment. Discov Appl Sci 2025; 7 : 193.
Ikwelle TA, Ihim AC, Ozuruoke DF et al. Multi-omics integration in personalized medicine: advancing laboratory diagnostics and precision therapeutics in the era of individualized healthcare. J Drug Deliv Ther 2025; 15 : 132–134.

Adresa pro korespondenci:

doc. RNDr. Judita Kinkorová, CSc.

Oddělení imunochemické diagnostiky FN Plzeň

Edvarda Beneše 13

301 00 Plzeň-Bory

e-mail: kinkorovaj@fnplzen.cz

Labels

Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist

Telemedicine video consultations in the Czech Republic and their practical implementation in outpatient practice

Colorectal cancer and comorbidities – implications for surgical practice

Obesity during pregnancy – health risks and prevention options

Periodontitida a diabetes mellitus 2. typu

Ancient sanctuary of Eileithyia, goddess of childbirth, on the island of Paros (Greece)

Professor Otto Piffl, the First Full Professor of Otology and Rhinology at the German University in Prague, passed away 100 years ago

MUDr. Václav Náprstek – zapomenutý hrdina

The personality of professor Otakar Štark in the context of the development of medical genetics in Czechoslovakia in the years 1950–1990

Pokyny pro autory a autorky Časopisu lékařů českých – výtah

Article was published in